financetom
Business
financetom
/
Business
/
TSMC posts forecast-beating Q3 revenue surge on AI boom
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TSMC posts forecast-beating Q3 revenue surge on AI boom
Oct 8, 2025 11:17 PM

*

Q3 revenue ahead of market forecast

*

Company to report full Q3 earnings on October 16

*

TSMC shares have soared 34% this year

(Adds details throughout)

TAIPEI, Oct 9 (Reuters) - TSMC, the world's largest

contract chipmaker, reported on Thursday third-quarter revenue

rose 30% year-on-year, beating the market forecast, as demand

for the company's products leapt on surging interest in

artificial intelligence applications.

Revenue for July-September came in at T$989.92 billion

($32.47 billion), according to Reuters calculations, compared

with T$759.69 billion in the year ago period.

The latest result handily topped an LSEG SmartEstimate of

T$973.26 billion drawn from 22 analysts, and was in the

mid-point of guidance of $31.8 billion to $33 billion issued by

TSMC in July in its last earnings call. TSMC only gives guidance

in U.S. dollars.

TSMC will report full third-quarter earnings on

October 16, including an updated outlook for the current quarter

and full year.

The company, whose customers include Nvidia ( NVDA ) and

Apple ( AAPL ), has been a major beneficiary of advances in AI,

which has more than offset the tapering off of pandemic-led

demand for chips used in consumer electronics like tablets.

TSMC's Taipei-listed shares have gained 34% so far this

year, compared with an 18.5% rise for the broader market

.

Taiwan's Foxconn, the world's largest contract

electronics maker and Nvidia's ( NVDA ) biggest server maker, has also

reported bumper sales, logging its highest-ever revenue for the

third quarter.

($1 = 30.4880 Taiwan dollars)

(Reporting by Ben Blanchard and Faith Hung; Editing by Jamie

Freed and Muralikumar Anantharaman)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Snowflake Unusual Options Activity For July 29
Snowflake Unusual Options Activity For July 29
Jul 29, 2024
Whales with a lot of money to spend have taken a noticeably bullish stance on Snowflake. Looking at options history for Snowflake we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 40% with bearish. From the overall spotted trades, 7 are...
Textron's Aviation Unit to Sell Three Beechcraft King Air 360C Aircraft to Gama Aviation
Textron's Aviation Unit to Sell Three Beechcraft King Air 360C Aircraft to Gama Aviation
Jul 29, 2024
11:01 AM EDT, 07/29/2024 (MT Newswires) -- Textron's ( TXT ) Textron Aviation unit said Monday it has signed an agreement with Gama Aviation to sell Gama three cargo door-equipped Beechcraft King Air 360C aircraft. Financial terms of the agreement weren't disclosed. Textron Aviation said it intends to deliver the aircraft next year. The aircraft is intended to help support...
Crocs' Margins Remain 'Most Likely' Source of Q2 Upside, Wedbush Securities Says
Crocs' Margins Remain 'Most Likely' Source of Q2 Upside, Wedbush Securities Says
Jul 29, 2024
11:04 AM EDT, 07/29/2024 (MT Newswires) -- Crocs' ( CROX ) most likely source of upside in Q2 remains its margins, like in recent quarters, as the company guided the period's EBIT margin conservatively, Wedbush Securities said in a Monday note. The company expects almost a 400 basis points decline in Q2 EBIT margin and Wedbush is modeling a Q2...
Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further
Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further
Jul 29, 2024
Ventyx Biosciences Inc ( VTYX ) stock is trading lower on Monday. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn’s disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract. The Phase 2 trial enrolled 109 participants randomized to one of two...
Copyright 2023-2026 - www.financetom.com All Rights Reserved